Rethinking the advantage of zero-HLA mismatches in unrelated living donor kidney transplantation: Implications on kidney paired donation

Michael Jin Casey, Xuerong Wen, Shehzad Rehman, Alfonso H. Santos, Kenneth A. Andreoni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Summary The OPTN/UNOS Kidney Paired Donation (KPD) Pilot Program allocates priority to zero-HLA mismatches. However, in unrelated living donor kidney transplants (LDKT) - the same donor source in KPD - no study has shown whether zero-HLA mismatches provide any advantage over >0 HLA mismatches. We hypothesize that zero-HLA mismatches among unrelated LDKT do not benefit graft survival. This retrospective SRTR database study analyzed LDKT recipients from 1987 to 2012. Among unrelated LDKT, subjects with zero-HLA mismatches were compared to a 1:1-5 matched (by donor age ±1 year and year of transplantation) control cohort with >0 HLA mismatches. The primary endpoint was death-censored graft survival. Among 32,654 unrelated LDKT recipients, 83 had zero-HLA mismatches and were matched to 407 controls with >0 HLA mismatches. Kaplan-Meier analyses for death-censored graft and patient survival showed no difference between study and control cohorts. In multivariate marginal Cox models, zero-HLA mismatches saw no benefit with death-censored graft survival (HR = 1.46, 95% CI 0.78-2.73) or patient survival (HR = 1.43, 95% CI 0.68-3.01). Our data suggest that in unrelated LDKT, zero-HLA mismatches may not offer any survival advantage. Therefore, particular study of zero-HLA mismatching is needed to validate its place in the OPTN/UNOS KPD Pilot Program allocation algorithm.

Original languageEnglish (US)
Pages (from-to)401-409
Number of pages9
JournalTransplant International
Volume28
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Unrelated Donors
Living Donors
Kidney Transplantation
Kidney
Graft Survival
Transplants
Tissue Donors
Survival
Kaplan-Meier Estimate
Proportional Hazards Models
Cohort Studies
Transplantation
Databases

Keywords

  • human leukocyte antigen
  • kidney
  • living donor
  • mismatch
  • paired donation
  • transplant

ASJC Scopus subject areas

  • Transplantation
  • Medicine(all)

Cite this

Rethinking the advantage of zero-HLA mismatches in unrelated living donor kidney transplantation : Implications on kidney paired donation. / Casey, Michael Jin; Wen, Xuerong; Rehman, Shehzad; Santos, Alfonso H.; Andreoni, Kenneth A.

In: Transplant International, Vol. 28, No. 4, 01.04.2015, p. 401-409.

Research output: Contribution to journalArticle

Casey, Michael Jin ; Wen, Xuerong ; Rehman, Shehzad ; Santos, Alfonso H. ; Andreoni, Kenneth A. / Rethinking the advantage of zero-HLA mismatches in unrelated living donor kidney transplantation : Implications on kidney paired donation. In: Transplant International. 2015 ; Vol. 28, No. 4. pp. 401-409.
@article{eeea50ea123244ba9c01a08d097bbe59,
title = "Rethinking the advantage of zero-HLA mismatches in unrelated living donor kidney transplantation: Implications on kidney paired donation",
abstract = "Summary The OPTN/UNOS Kidney Paired Donation (KPD) Pilot Program allocates priority to zero-HLA mismatches. However, in unrelated living donor kidney transplants (LDKT) - the same donor source in KPD - no study has shown whether zero-HLA mismatches provide any advantage over >0 HLA mismatches. We hypothesize that zero-HLA mismatches among unrelated LDKT do not benefit graft survival. This retrospective SRTR database study analyzed LDKT recipients from 1987 to 2012. Among unrelated LDKT, subjects with zero-HLA mismatches were compared to a 1:1-5 matched (by donor age ±1 year and year of transplantation) control cohort with >0 HLA mismatches. The primary endpoint was death-censored graft survival. Among 32,654 unrelated LDKT recipients, 83 had zero-HLA mismatches and were matched to 407 controls with >0 HLA mismatches. Kaplan-Meier analyses for death-censored graft and patient survival showed no difference between study and control cohorts. In multivariate marginal Cox models, zero-HLA mismatches saw no benefit with death-censored graft survival (HR = 1.46, 95{\%} CI 0.78-2.73) or patient survival (HR = 1.43, 95{\%} CI 0.68-3.01). Our data suggest that in unrelated LDKT, zero-HLA mismatches may not offer any survival advantage. Therefore, particular study of zero-HLA mismatching is needed to validate its place in the OPTN/UNOS KPD Pilot Program allocation algorithm.",
keywords = "human leukocyte antigen, kidney, living donor, mismatch, paired donation, transplant",
author = "Casey, {Michael Jin} and Xuerong Wen and Shehzad Rehman and Santos, {Alfonso H.} and Andreoni, {Kenneth A.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/tri.12495",
language = "English (US)",
volume = "28",
pages = "401--409",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Rethinking the advantage of zero-HLA mismatches in unrelated living donor kidney transplantation

T2 - Implications on kidney paired donation

AU - Casey, Michael Jin

AU - Wen, Xuerong

AU - Rehman, Shehzad

AU - Santos, Alfonso H.

AU - Andreoni, Kenneth A.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Summary The OPTN/UNOS Kidney Paired Donation (KPD) Pilot Program allocates priority to zero-HLA mismatches. However, in unrelated living donor kidney transplants (LDKT) - the same donor source in KPD - no study has shown whether zero-HLA mismatches provide any advantage over >0 HLA mismatches. We hypothesize that zero-HLA mismatches among unrelated LDKT do not benefit graft survival. This retrospective SRTR database study analyzed LDKT recipients from 1987 to 2012. Among unrelated LDKT, subjects with zero-HLA mismatches were compared to a 1:1-5 matched (by donor age ±1 year and year of transplantation) control cohort with >0 HLA mismatches. The primary endpoint was death-censored graft survival. Among 32,654 unrelated LDKT recipients, 83 had zero-HLA mismatches and were matched to 407 controls with >0 HLA mismatches. Kaplan-Meier analyses for death-censored graft and patient survival showed no difference between study and control cohorts. In multivariate marginal Cox models, zero-HLA mismatches saw no benefit with death-censored graft survival (HR = 1.46, 95% CI 0.78-2.73) or patient survival (HR = 1.43, 95% CI 0.68-3.01). Our data suggest that in unrelated LDKT, zero-HLA mismatches may not offer any survival advantage. Therefore, particular study of zero-HLA mismatching is needed to validate its place in the OPTN/UNOS KPD Pilot Program allocation algorithm.

AB - Summary The OPTN/UNOS Kidney Paired Donation (KPD) Pilot Program allocates priority to zero-HLA mismatches. However, in unrelated living donor kidney transplants (LDKT) - the same donor source in KPD - no study has shown whether zero-HLA mismatches provide any advantage over >0 HLA mismatches. We hypothesize that zero-HLA mismatches among unrelated LDKT do not benefit graft survival. This retrospective SRTR database study analyzed LDKT recipients from 1987 to 2012. Among unrelated LDKT, subjects with zero-HLA mismatches were compared to a 1:1-5 matched (by donor age ±1 year and year of transplantation) control cohort with >0 HLA mismatches. The primary endpoint was death-censored graft survival. Among 32,654 unrelated LDKT recipients, 83 had zero-HLA mismatches and were matched to 407 controls with >0 HLA mismatches. Kaplan-Meier analyses for death-censored graft and patient survival showed no difference between study and control cohorts. In multivariate marginal Cox models, zero-HLA mismatches saw no benefit with death-censored graft survival (HR = 1.46, 95% CI 0.78-2.73) or patient survival (HR = 1.43, 95% CI 0.68-3.01). Our data suggest that in unrelated LDKT, zero-HLA mismatches may not offer any survival advantage. Therefore, particular study of zero-HLA mismatching is needed to validate its place in the OPTN/UNOS KPD Pilot Program allocation algorithm.

KW - human leukocyte antigen

KW - kidney

KW - living donor

KW - mismatch

KW - paired donation

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=84926383451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926383451&partnerID=8YFLogxK

U2 - 10.1111/tri.12495

DO - 10.1111/tri.12495

M3 - Article

C2 - 25440520

AN - SCOPUS:84926383451

VL - 28

SP - 401

EP - 409

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 4

ER -